16 However, a portion of spending on these therapies is expected to persist for the non-weight loss indications (e.g., major adverse cardiovascular events [MACE], metabolic dysfunction associated steatohepatitis [MASH], and obstructive sleep apnea [OSA])
Without targeted policy interventions, such as expanded insurance coverage or income-based subsidy programs, the benefits of GLP-1 medications may continue to accrue disproportionately to higher-income populations, leaving behind the very communities most affected by obesity
You only pay if the physician actually writes a prescription
Targeting Visceral Fat Visceral fat wraps around internal organs and presents greater health risks than subcutaneous fat
The mechanism by which people lose weight is typically through a decreased appetite
Alternatives for microdosing GLP-1 medications include a slower titration phase, switching to a different medication, or managing the side effects with lifestyle modifications